Aurora Cannabis adds high-THC cannabis strain in Poland

Executive Summary

• Aurora Cannabis Inc. has launched "Black Jelly," a proprietary high-potency medical cannabis cultivar, in the Polish market.
• The product is part of the "Cannabis flos Aurora" brand portfolio and is grown in Aurora’s Canadian GACP and EU-GMP certified facilities.
• Black Jelly is a high-THC sativa with a specific cannabinoid profile (THC 27%, CBD <1%) and distinct terpene characteristics, targeting prescribers and patients in Europe's fastest-growing medical cannabis market.

Key Details

• Product Name: Black Jelly (proprietary cultivar).
• Brand Portfolio: Joins "Farm Gas" and "Sourdough" under the "Cannabis flos Aurora" brand.
• Market: Poland (launched Dec. 11, 2025).
• Cannabinoid Profile: THC 27%, CBD less than 1%.
• Genetics: High-THC sativa derived from Alien Cake 3030 * T037.
• Physical Characteristics: Dense, large flowers with green and orange hues.
• Terpene Profile: Sweet black liquorice and fruity undertones.
• Production Standards: Grown and manufactured in Aurora's Canadian GACP (Good Agricultural and Collection Practices) and EU-GMP (European Union Good Manufacturing Practice) certified facilities.
• Processing: Crafted using premium hang-drying and curing techniques.
• Strategic Context: Aurora aims to leverage its advanced genetic breeding program and global cultivation excellence to support patient access and market growth in Europe.

Notable Quotes

• "Aurora is uniquely positioned to bring this novel proprietary cultivar to the Polish market thanks to the company's advanced genetic breeding program and unmatched global cultivation excellence," said Andreas Dotterweich, senior vice-president of Aurora Europe.
• "We deeply understand that prescribers want reliable, high-potency medical cannabis options for their patients, and we're proud to offer superior products that consistently meet prescriber and patient needs."